A Phase 1/2 interventional study of HS_SW01 cells injection and HS_SW01 cells injection in Primary Ovarian Insufficiency (Poi), sponsored by Shenzhen Huishan Biotechnology Co., Ltd.. Not yet recruiting. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-27.
Sponsored by Shenzhen Huishan Biotechnology Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS_SW01 cells injection) in patients with Primary Ovarian Insufficiency (POI).
Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS_SW01 cells injection) in patients with Primary Ovarian Insufficiency (POI).
Participants will be required to sign the informed consent form and will only be assigned to the study and enrolled after undergoing a series of tests and meeting the inclusion and exclusion criteria of the protocol.
This trial consists of a Phase I dose-escalation stage and a Phase II dose-expansion stage. Phase I is a randomized, double-blind, placebo-controlled design in which all participants receive background therapy plus a single intravenous infusion of HS_SW01 cells injection (1.0×10\^6 cells/kg, 2.0×10\^6 cells/kg, 3.0×10\^6 cells/kg) or placebo, with 4-7 participants per dose group. A "3+3" dose-escalation design is used to evaluate safety, tolerability, pharmacokinetics, and immunogenicity across the three dose groups. In Phase II, the optimal biological dose (OBD) identified from the Phase I escalation study will serve as the recommended Phase II dose (RP2D) to preliminarily assess efficacy while continuing safety monitoring, providing a basis for subsequent clinical trials.
Eligible participants are patients with POI aged ≥18 to \<40 years who meet all inclusion criteria and none of the exclusion criteria.
181 studies on the registry are indexed under Primary Ovarian Insufficiency; 48 are open to participants now.
This study's planned enrollment of 21 is below the median of 48 across 113 interventional studies indexed under Primary Ovarian Insufficiency.
Browse Primary Ovarian Insufficiency studies →Shenzhen Huishan Biotechnology Co., Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following conditions within 3 months prior to enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous inject MSCs
Drug: HS_SW01 cells injection
intravenous inject MSCs
Drug: HS_SW01 cells injection
intravenous inject MSCs
Drug: HS_SW01 cells injection
A single dose of 1×10\^6 cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.
A single dose of 2×10\^6 cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.
A single dose of 3×10\^6 cells/kg of HS\_SW01 cells injection will be given by intravenous infusion.
The incidence of DLT
Incidence of dose-limiting toxicities (DLTs) within 28 days following study drug administration.
Time frame: Within 28 Days
Changes of the Anti-Müllerian hormone (AMH) serum level from baseline.
Evaluate the AMH serum level by blood sampling at baseline and at Week 4, Week 12 and Week 24 after administration to assess changes of the Anti-Müllerian hormone (AMH) serum level from baseline.
Time frame: Baseline, Week 4, Week 12, Week 24
Changes of the Follicle Stimulating Hormone (FSH) serum level from baseline.
Evaluate the FSH serum level by blood sampling at baseline and at Week 4, Week 12 and Week 24 after administration to assess changes of the Follicle Stimulating Hormone (FSH) serum level from baseline.
Time frame: Baseline, Week 4, Week 12, Week 24
Changes of Luteinizing Hormone (LH) serum level from baseline.
Evaluate the LH serum level by blood sampling at baseline and at Week 4, Week 12 and Week 24 after administration to assess changes of Luteinizing Hormone (LH) serum level from baseline.
Time frame: Baseline, Week 4, Week 12, Week 24
Changes of the Estradiol (E2) serum level from baseline.
Evaluate the E2 serum level by blood sampling at baseline and at Week 4, Week 12 and Week 24 after administration to assess changes of the Estradiol (E2) serum level from baseline.
Time frame: Baseline, Week 4, Week 12, Week 24
Changes of the Antral Follicle Counting (AFC) from baseline.
Evaluate the Antral Follicle Counting (AFC) by sonography at baseline and at Week 4, Week 12 and Week 24 after administration to assess Changes of the Antral Follicle Counting (AFC) from baseline .
Time frame: Baseline, Week 4, Week 12, Week 24
Changes of the Ovarian Volume (OV) from baseline.
Evaluate the Ovarian Volume (OV) by sonography at baseline and at Week 4, Week 12 and Week 24 after administration to assess Changes of the Ovarian Volume (OV) from baseline.
Time frame: Baseline, Week 4, Week 12, Week 24
Changes of the menstrual function indicators from baseline.
Menstrual function indicators will be recorded via patient diaries or visit questionnaires to evaluate the recovery of menstruation following treatment. The form includes the date of menstrual onset, duration of menstruation (in days), menstrual regularity (regular/irregular; regular defined as cycle fluctuation ≤7 days), and associated symptoms (dysmenorrhea/other, with descriptive notes).Menstrual blood loss will be assessed using the Pictorial Blood Loss Assessment Chart (PBAC), which records, for each menstrual cycle, the type and number of sanitary products used daily, the frequency of clots passed into the toilet, and the total menstrual blood loss (in mL). Menstrual function recovery is defined as meeting all of the following criteria: (1)At least two consecutive cycles of menstrual bleeding after treatment discontinuation;(2)Cycle length restored to 21-35 days;(3)Menstrual blood volume returned to pre-illness levels compared with the subject's own baseline.
Time frame: Up to Week 24
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Primary Ovarian Insufficiency →
Shenzhen Huishan Biotechnology Co., Ltd.